DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Glioblastoma progression is hindered by melatonin-primed mesenchymal stromal cells through dynamic intracellular and extracellular reorganizations
Rationale: Glioblastoma (GBM) is the most fatal form of brain cancer and its treatment represents a persistent challenge. Mesenchymal stromal cells (MSCs) have been explored as therapeutic tools in cancer management owing to their tumor-homing abilities. However, their clinical application is limited due to the controversial role of MSCs in carcinogenesis. This study investigates how MSCs influence tumor behavior and explores the synergistic anticancer effects in combination with melatonin (Mel).
Methods: Orthotopic and subcutaneous GBM xenograft mouse models were used to assess the antitumor effect of Mel pre-treated MSCs (MSCMel). Histological, immunohistochemical, and ultrastructural analyses were conducted to identify phenotypic changes in tumors. Through a set of in vitro assays, including direct and indirect co-cultures, dynamic single-cell tracking and tumorsphere assay, we explored the impact of MSCMel on primary and non-primary GBM cells. Transcriptomic profiling was used to identify genes and pathways modulated by this synergistic therapy.
Results: MSCMel delayed tumor growth in mice and increased collagen deposition. Additionally, MSCMel showed enhanced capacity to prevent GBM cell migration compared to untreated MSCs. Molecular analysis identified genes and proteins related to cell migration, cytoskeletal dynamics and extracellular matrix remodeling in GBM cells exposed to MSCMel, including reduced vimentin expression. Finally, a genetic signature associated with the clinical outcomes of GBM patients was identified.
Conclusions: Our study demonstrates that melatonin enhances the anticancer properties of MSCs, providing new insights into their interaction with GBM cells and tumor environment. These findings offer valuable guidance for advancing MSC-based therapies in clinical practice., This research was funded by the Institute of
Health Carlos III, co-funded by Fondos FEDER
(PI23/00315, PI20/00341 and CP19/00046 to VC-G)
and the Asociación Española Contra el Cancer
(IDEAS20051CAPI to VC-G). LO-M is supported by
the Spanish Ministry of Science, Innovation and
Universities (FPU19/04703). JMS-P was supported by
the Consejería de Transformación Económica,
Industria, Conocimiento y Universidades of Junta de
Andalucia, co-funded by Fondos FEDER
(POSTDOC/21/00424) and the Institute of Health
Carlos III, co-funded by Eropean Union
(CD23/00104). CP-M is supported by the Asociación
Pablo Ugarte. RM-G is supported by the Asociación
Española Contra el Cancer (PRDVA222457MORA).
RV-D. was supported by Grant PID2021-
124251OB-I00 and Grant RED2022-134927-T funded
by MICIU/AEI/10.13039/501100011033 and by
ERDF/UE. AM-M is supported by the Ministerio de
Ciencia e Innovación (PID2021-123965OB-100). HG-C
is supported by the National Institute of Neurological
Disorders and Stroke and internal Mayo Clinic funds.
JMG-V was supported by the Valencian Council for
Education, Culture, University and Employment
(CIPROM/2023/053)., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-124251OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 RED2022-134927-T
,
AEI PID2021-123965OB-I00
DOI: http://hdl.handle.net/10261/384152, https://api.elsevier.com/content/abstract/scopus_id/85219576511
HANDLE: http://hdl.handle.net/10261/384152, https://api.elsevier.com/content/abstract/scopus_id/85219576511